Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling

P-F Zhang1,4, K-S Li2,4, Y-h Shen1,4, P-T Gao1,4, Z-R Dong1,4, J-B Cai1, C Zhang1, X-Y Huang1, M-X Tian1, Z-Q Hu1, D-M Gao1, J Fan1,3, A-W Ke1 and G-M Shi1

Galectin-1 (Gal-1) is involved in several pathological activities associated with tumor progression and chemoresistance, however, the role and molecular mechanism of Gal-1 activity in hepatocellular carcinoma (HCC) epithelial–mesenchymal transition (EMT) and sorafenib resistance remain enigmatic. In the present study, forced Gal-1 expression promoted HCC progression and sorafenib resistance. Gal-1 elevated \( \alpha_v\beta_3 \)-integrin expression, leading to AKT activation. Moreover, Gal-1 overexpression induced HCC cell EMT via PI3K/AKT cascade activation. Clinically, our data revealed that Gal-1 overexpression is correlated with poor HCC survival outcomes and sorafenib response. These data suggest that Gal-1 may be a potential therapeutic target for HCC and a biomarker for predicting response to sorafenib treatment.

Cell Death and Disease (2016) 7, e2201; doi:10.1038/cddis.2015.324; published online 21 April 2016

Hepatocellular carcinoma (HCC) is the fifth most common cancer and third leading cause of cancer-related deaths worldwide. These dismal outcomes result from its high recurrence following curative liver resection and its notorious resistance to systemic chemotherapy. In the past several decades, molecular therapies targeting signaling cascades involved in HCC development and progression have been explored, and sorafenib has been used as a first-line treatment for advanced HCC patients. Problematically, clinical trials have shown that on average, these patients only experience 3 months of benefits from sorafenib treatment. Moreover, none of the tested drugs showed positive responses as either first- or second-line treatment after sorafenib resistance. Consequently, it is imperative that the molecular mechanisms involved in sorafenib resistance are identified and used to improve HCC response to sorafenib.

Galectin-1 (Gal-1), a 14.5-kDa protein, is regulated by HIF-1 and has vital protumorigenic roles within the tumor microenvironment. Dysregulation of Gal-1 expression is associated with resistance to chemotherapy through H-Ras/Raf/extracellular signal-regulated kinase (ERK) pathway activation. Gal-1 overexpression also mediates migration and invasion via increased phosphorylation of AKT, mTOR and p70 kinases in cancer cells. Moreover, sorafenib response is impaired in HCC with dysregulated p-ERK and p-AKT activation.

Previous studies have confirmed that integrins facilitate tumor metastasis and influence the malignant phenotypes of several cancers. Integrins are predominantly expressed in epithelial cells where they serve as laminin receptors, and the \( \alpha_v \) and \( \beta_3 \) subunits are both upregulated in cancer progression and therapy resistance.

In this study, we found that forced Gal-1 expression induces EMT through an \( \alpha_v\beta_3 \)-integrin/FAK/PI3K/AKT signaling pathway in HCC cells. Moreover, high levels of Gal-1 are associated with impaired sorafenib response and reduced OS.

1 Key Laboratory of Carcinogenesis and Cancer Invasion, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Ministry of Education, Shanghai 200032, China; 2 State Key Laboratory of Oncogenes & Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao tong University School of Medicine, Shanghai 200032, China and 3 Cancer Center, Institutes of Biomedical Sciences, Fudan University, Shanghai 200031, China

*Corresponding author: G-M Shi or A-W Ke, Key Laboratory of Carcinogenesis and Cancer Invasion, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Ministry of Education, 180 Fengl In Road, Shanghai 200032, China. Tel: +86 21 64037181; Fax: +86 21 64037181; E-mail: shi.guoming@zs-hospital.sh.cn or ke.aiwu@zs-hospital.sh.cn

These authors contributed equally to this work.

**Abbreviations:** HCC, hepatocellular carcinoma; Gal-1, galectin-1; EMT, epithelial–mesenchymal transition; HIF-1, Hypoxia-inducible factor-1; ROS, reactive oxygen species; ERK, extracellular regulated protein kinase; OS, overall survival; RFS, recurrence-free survival; PI3K, phosphatidylinositol-3-kinase; real-time PCR, real-time polymerase chain reaction; shRNA, short hairpin RNA

Received 27.5.15; revised 28.9.15; accepted 05.10.15; Edited by M Agostini
Results

Gal-1 is upregulated in human HCC and is correlated with poor prognosis. To explore the role of Gal-1 in HCC progression, we first evaluated Gal-1 expression in various human HCC cell lines. We found that Gal-1 protein expression was significantly increased in highly metastatic cell lines (MHCC97H and HCCLM3) compared with low metastatic HCC cell lines (Hep3B and Huh-7; Figure 1a). We then performed immunohistochemistry (IHC) analysis of Gal-1 expression in 209 HCC patients, finding that Gal-1 expression was significantly higher in HCC tissues compared with adjacent normal tissues (Figure 1b). For further analysis, patients were separated into groups with high (Gal-1-high, moderate and strong; \( n = 128 \)) and low Gal-1 expression (Gal-1-low, negative and weak; \( n = 81 \)) groups. There was a striking, and statistically significant inverse association between Gal-1 intensity and recurrence-free survival (RFS; \( P = 0.008 \); Figure 1c), and to a less extent, over survival (OS) (\( P = 0.006 \); Figure 1d). The respective median RFS and OS time for Gal-1-high patients were 40.5 and 47.7 months, compared with 53.1 and 57.8 months for Gal-1-low patients. Multivariate analysis revealed that Gal-1 intensity in tumors was an independent predictor for both RFS and OS (Supplementary Tables 2 and 3), therefore, Gal-1 expression is a valuable predictor for recurrence and survival in HCC patients.

Gal-1 promotes HCC cell invasion in vitro and lung metastasis in vivo. Western blot analysis was used to confirm stable upregulation of Gal-1 expression in Hep3B and Huh-7 cells, and Gal-1 knockdown in HCCLM3 and MHCC97H cells (Figures 2a and b). In vitro invasion assays revealed that the Huh-7- Gal-1 and Hep3B-Gal-1 groups had significantly larger populations of invasive cells compared with the control cells (Figure 2c). In contrast, the population of invasive cells in the HCCLM3-Gal-1 shRNA and

---

**Figure 1**  Gal-1 is overexpressed in HCC tissues and its expression is correlated with HCC clinical outcome. (a) Gal-1 expression in several HCC lines was examined using western blot analysis. Tubulin was used as a control for loading. (b) Gal-1 immunostaining using 3,3′-diaminobenzidine (DAB; brown) in HCC tissues and adjacent normal liver. (c,d) The cumulative recurrence and overall survival rates of 209 patients with HCC were compared between Gal-1-low and -high groups using Kaplan–Meier methods (log-rank test). Scale bar, 100 μm
Figure 2  High expression of Gal-1 promotes HCC metastasis both in vitro and in vivo. (a,b) Gal-1 expression in HCC cells was modified by shRNA interference and cDNA transfection. (c,d) Cancer cell invasion was measured using transwell assays. (e) Representative views of lung tissue sections from each group; pulmonary metastasis rates are shown. *P < 0.05, **P < 0.05. Scale bar, 100 μm
MHCC97H-Gal-1 shRNA groups was significantly reduced compared with the control (Figure 2d). Following orthotropic transplantation of Hep3B-Gal-1, Huh-7-Gal-1 and mock cells into nude mice, all groups successfully formed liver tumors. Pulmonary metastases occurred in both the Huh-7-Gal-1 (5/6) and Hep3B-Gal-1 (4/6) groups; a representative lung metastasis is shown in Figure 2e. In contrast, pulmonary metastases were not observed in the Hep3B-mock and Huh-7-mock groups. Together, the in vitro and in vivo data show that Gal-1 significantly contributes to HCC tumor metastasis.

Gal-1 induces αvβ3-integrin expression and FAK/PI3K/AKT signaling activation. To characterize the molecular pathways affected by Gal-1 in HCC cells, we examined two microarray-based global gene expression profiling studies of cancer cells with endogenous forced Gal-1 levels or Gal-1 knockdown.\textsuperscript{21,22} We speculated that the αv- and β3-integrin subunits may be candidate Gal-1 targets. Real-time PCR and western blot analysis confirmed that the mRNA and protein expression levels of both the αv- and β3-integrin subunits were reduced in HCCLM3 and MHCC97H cells with Gal-1 knockdown, whereas Gal-1 overexpression increased αv- and β3-integrin subunit levels in Huh-7 and Hep3B cells (Figures 3a and f). Furthermore, the phosphorylation of FAK, a downstream integrin kinase, was also increased in Huh-7 and Hep3B cells overexpressing Gal-1, while FAK activation was reduced in HCCLM3 and MHCC97H cells with Gal-1 knockdown (Figures 3e and f). The downstream FAK

### Figure 3

Gal-1 overexpression induces FAK/PI3K/AKT signaling hyperactivation in HCC cells. (a,b) Forced Gal-1 expression enhanced αv- and β3-integrin mRNA expression in HCC cells. (c) Forced Gal-1 expression increased protein expression of αv and β3 integrin, p-FAK, and p-AKT in HCC cells. (d,e) mRNA expression levels of αv and β3 integrin were reduced in HCC cells treated with Gal-1 shRNA. (f) Protein expression levels of αv and β3 integrin, p-FAK, and p-AKT were reduced in HCC cells treated with Gal-1 shRNA. (g) Immunostaining (DAB) for αv and β3 integrin in HCC and adjacent normal liver tissues. Data are represented as the mean ± S.D., n = 3. *P < 0.05, and **P < 0.01. Scale bar, 100 μm.
signaling molecule AKT was also activated in Huh-7 and Hep3B cells overexpressing Gal-1, while AKT activation was reduced in HCCLM3 and MHCC97H cells with Gal-1 knockdown (Figures 3e and f).

We then examined αvβ3-integrin expression in a cohort of 209 HCC patients, finding that αv and β3-integrin subunit staining was localized to the plasma membrane (Figure 3g). We found that 89 of 209 HCC cases (42.6%) exhibited high levels of both the αv and β3-integrin subunits. Strikingly, IHC analysis showed that patients with HCC and Gal-1 overexpression tended to have higher levels of αv and β3-integrin subunits. These results indicate that Gal-1 overexpression may promote tumor progression by inducing αv and β3-integrin subunit expression in HCC.

To further explore the relationship between Gal-1, αv and β3 integrin and p-AKT, we examined tissue from 209 HCC cases for Gal-1, αv and β3 integrin, and p-AKT expression. The expression patterns of these proteins in HCC tissues revealed a positive correlation between protein levels of Gal-1 with αv integrin (P = 0.0119, R² = 0.2056), β3 integrin (P = 0.0242, R² = 0.1686) and p-AKT (P = 0.0194, R² = 0.1802; Supplementary Figure 1).

High Gal-1 expression induces FAK and AKT hyperactivation by selectively amplifying the αvβ3-integrin signal. Gal-1 increases αvβ3-integrin expression and activates FAK/PI3K/AKT signaling in HCC cells, therefore, we examined whether the oncogenic effects of Gal-1 could be reversed by loss of either the αv- or β3-integrin subunits. We first transfected Huh-7- Gal-1 and Hep3B-Gal-1 cells with an αv-integrin shRNA plasmid and validated the shRNA knockdown efficacy using real-time PCR and western blot analysis (Figures 4a and c). Knockdown of αv integrin reduced Gal-1 overexpression-mediated FAK and AKT phosphorylation and invasion in vitro (Figures 4c and e). We then transfected Huh-7-Gal-1 and Hep3B-Gal-1 cells with a β3-integrin shRNA plasmid, and observed results similar to those produced by integrin αv knockdown (Figures 4b and e). Interestingly, knockdown of αvβ3-integrin expression was sufficient to block HCCLM3 and MHCC97H cell invasion (Supplementary Figure 2). These results indicate that Gal-1 might regulate the FAK/PI3K/AKT pathway by upregulating αvβ3-integrin expression.

Gal-1 overexpression induces HCC EMT through FAK/PI3K/AKT pathway hyperactivation. On the basis of the association between Gal-1 expression and HCC progression in vivo and in vitro, and given that EMT is considered to be a striking feature of most cancers and has an important role in cancer migration and invasion, we examined the expression of epithelial and mesenchymal markers, as well as of other molecules thought to induce EMT in cancer cells. As shown in Figure 5a, Huh-7- Gal-1 and Hep3B-Gal-1 cells expressed reduced levels of the epithelial marker E-cadherin compared with Huh-7-mock and Hep3B-mock cells. In contrast, the mesenchymal markers vimentin and N-cadherin were significantly upregulated in Huh-7- Gal-1 and Hep3B-Gal-1 cells compared with Huh-7-mock and Hep3B-mock cells. HCCLM3 is a highly metastatic cell line that expresses low levels of E-cadherin and high levels of vimentin and is thus thought to present a mesenchymal-like phenotype.23 Interestingly, E-cadherin levels were higher in HCCLM3-Gal-1 shRNA cells than in HCCLM3-NC shRNA cells, while the mesenchymal-associated genes vimentin and N-cadherin were downregulated in HCCLM3-Gal-1 shRNA cells (Figure 5b). A previous study reported that the hyperactivation of PI3K signaling is responsible for EMT, primarily via the PI3K/AKT/Snail/PTEN feedback loop.5 The results obtained thus far indicated that the FAK/PI3K/AKT signaling may mediate HCC EMT owing to high expression of Gal-1. We aimed to test this idea by downregulating endogenous AKT and inhibiting PI3K signaling using a PI3K inhibitor, LY294002 (20 μmol/L). As anticipated, Huh-7- Gal-1 and Hep3B-Gal-1 cells lacking AKT (due to shRNA or inhibition of PI3K signaling) expressed high levels of E-cadherin and low levels of vimentin and N-cadherin compared with control cells (Figures 5c and d).

Furthermore, the Huh-7- Gal-1 and Hep3B-Gal-1 cells lacking either αv- or β3-integrin expressed high levels of E-cadherin and low levels of vimentin and N-cadherin compared with control cells (Figures 5e and f).

Gal-1 expression is inversely correlated with HCC sensitivity to sorafenib. To examine the role of Gal-1 in HCC cell sensitivity to sorafenib, we generated Huh-7 and Hep3B cells overexpressing Gal-1. For Huh-7-Gal-1 and Huh-7-mock cells, the sorafenib IC₅₀ values were 7.12 ± 0.72 μM and 1.52 ± 0.40 μM, respectively (P < 0.05; Figure 6a); for Hep3B-Gal-1 and Hep3B-mock cells, the sorafenib IC₅₀ values were 3.65 ± 0.77 μM and 0.92 ± 0.23 μM, respectively (P < 0.05; Figure 6b). Together, these data suggest that Gal-1 overexpression leads to comparative HCC cell resistance to sorafenib. To further elucidate the role of Gal-1 in HCC cell resistance to sorafenib, HCCLM3 and MHCC97H cells, which exhibit high levels of Gal-1 protein expression, were treated with Gal-1 shRNA. For HCCLM3-Gal-1 shRNA and HCCLM3-NC shRNA cells, the sorafenib IC₅₀ values were 4.11 ± 1.09 μM and 22.13 ± 2.37 μM (P < 0.05), respectively (Figure 6c); for MHCC97H Gal-1 shRNA and MHCC97H NC shRNA cells, the sorafenib IC₅₀ values were 1.78 ± 0.45 μM and 5.64 ± 0.61 μM (P < 0.05), respectively (Figure 6d).

We then analyzed retrospective data from 30 advanced recurrent HCC patients receiving combined sorafenib and transarterial chemoembolization therapy who had undergone liver resection 2 – 60 months before the combined therapy; patient demographics (Supplementary Table 4) and OS were recorded. Gal-1 expression levels were then measured (Figure 6e), and Kaplan–Meier survival analysis indicated that the OS probability for the Gal-1-high group was much lower than that for the Gal-1-low group (Figure 6f). The median OS was 9.0 months in the Gal-1-high group and 14.0 months in the Gal-1-low group (Gal-1-high group hazard ratio 2.879; 95% confidence interval, 1.019–6.271; P < 0.05); therefore, we conclude that high levels of Gal-1 lead to HCC sorafenib resistance.

Discussion
The majority of our results in this study reinforce the notion that Gal-1 is a positive regulator of HCC progression. First, Gal-1 promoted HCC invasion in vitro and in vivo; second, Gal-1 overexpression fostered HCC progression by inducing EMT;
and third, forced Gal-1 expression reduced HCC sensitivity to sorafenib. We also demonstrate for the first time that Gal-1 enhanced αvβ3-integrin expression, which activates FAK/PI3K/AKT signaling. Clinically, we found that Gal-1 expression was correlated with overall patient survival and disease recurrence. Moreover, we demonstrated that Gal-1 overexpression activates FAK/PI3K/AKT signaling to induce HCC EMT. The above results support the notion that Gal-1 has a vital role in HCC progression.

A recent study showed that forced Gal-1 expression resulted in enhanced H-Ras-GTP membrane association, an increased number of Raf-1 recruitment sites, triggered sustained MEK-ERK pathway activation and enhanced cell transformation.24 The Ras-ERK pathway is required for EMT and contributes to the maintenance of an undifferentiated/mesenchymal state in tumor cells. This pathway cooperates with other pathways to promote expression of EMT-related genes, including mesenchymal genes and transcriptional...
repressors of epithelial genes. Consequently, H-Ras may be a potential target against Gal-1-induced HCC progression. Moreover, Gal-1 activates NF-κB in kidney cancer, inducing CXCR4 expression. The SDF-1/CXCR4 axis can trigger EMT in glioblastoma, meaning that CXCR4 could be another downstream target that mediates Gal-1-induced HCC progression; however, our results indicate that forced expression of Gal-1 in HCC cells is accompanied by an upregulation of αvβ3-integrin mRNAs and proteins. Furthermore, αvβ3-integrin knockdown reversed the mesenchymal phenotype conferred by Gal-1 overexpression, suggesting that Gal-1 can induce EMT by upregulating αvβ3 integrin. Using gene expression analysis, we demonstrated that Gal-1 overexpression induces FAK/P13K/AKT signaling hyperactivity by upregulating αvβ3 integrin. Therefore, we conclude that αvβ3 integrin has a critical role in Gal-1-induced HCC progression.

EMT is regulated by upstream pathways including P13K/AKT, MAPK, and TGF-β. Emerging evidence has suggested that EMT is involved in cancer chemoresistance and that inhibiting EMT can reverse this resistance. Moreover, EMT has been reported to function in HCC resistance to sorafenib and hyperactive P13K/AKT signaling was one of the primary causes. These previous studies indicate that P13K/AKT signaling hyperactivity may function in Gal-1-induced HCC resistance to sorafenib. In the present study we showed that Gal-1 overexpression leads to comparative HCC cell resistance to sorafenib in vitro, furthermore, despite a small cohort, clinical data also indicate that high levels of Gal-1 lead to HCC sorafenib resistance.

In conclusion, we provide insight into the biological function of Gal-1 signaling in HCC and demonstrate that Gal-1 overexpression activates the FAK/P13K/AKT pathway by upregulating expression of αvβ3 integrin, leading to enhanced HCC invasion via EMT and sorafenib resistance. Consequently, our study suggests that targeting Gal-1 in a subset of HCCs would be an optimal therapeutic strategy and suggests that Gal-1 may be a biomarker for predicting responsiveness to sorafenib treatment.

Figure 5  Gal-1 overexpression mediated HCC cell EMT via P13K/AKT signaling. (a,b) EMT markers in cells expressing high and low levels of Gal-1 (Huh-7- Gal-1 versus Huh-7-mock, Hep3B-Gal-1 versus Hep3B-mock, and HCCLM3-NC shRNA versus HCCLM3-Gal-1 shRNA). (c,d) Modulation of AKT expression and treatment with LY294002 reversed Gal-1 overexpression-mediated EMT in Huh-7- Gal-1 and Hep3B-Gal-1 cells. (e,f) Modulation of αv- and β3-integrin expression reversed Gal-1-overexpression-mediated EMT in Huh-7- Gal-1 and Hep3B-Gal-1 cells. All experiments were repeated at least three times.
Gal-1 induces HCC EMT and sorafenib resistance

**Materials and Methods**

**Cell lines and clinical samples.** The human HCC cell lines Huh-7, Hep3B, SK-Hep-1, HepG2, and PLC/PRF/5 were purchased from the American Type Culture Collection (Manassas, VA, USA). SMMC-7721 was preserved in our institute, and HCCLM3 and MHCC97H were established in the Liver Cancer Institute of the Zhongshan Hospital of Fudan University (Shanghai, China). All of the cell lines were routinely maintained.

Paraffin-embedded specimens of normal human liver and HCC tissues were obtained from the Zhongshan Hospital of Fudan University (Clinopathological characteristics were listed in Supplementary Table 1) and used for IHC. Sample collections were performed after receiving approval from the institutional ethics review committee of the Zhongshan Hospital of Fudan University, and no patients had undergone chemotherapy before surgery. Surgical evaluation was used to determine the clinical stage and presence of metastases, and pathologists performed histopathologic analysis to assess the cancer type and grade.

**Transwell invasion assay.** Cell invasion was measured using the transwell matrigel invasion assay. For Matrigel invasion assays, cells were suspended in DMEM without serum and then placed in the cell culture insert precoated with matrigel (BD Biosciences, San Jose, CA, USA). Warmed culture media containing DMEM without serum and then placed in the cell culture insert precoated with matrigel invasion assay. For Matrigel invasion assays, cells were suspended in 5% CO₂, fixed with 4% paraformaldehyde and stained with 0.1% crystal violet 10% FBS was added to the well, and the cells were then incubated for 24 h at 37 °C. The number of cells in five randomly selected areas.

**In vivo tumor invasion and metastasis assays.** Male athymic BALB/c nude mice were used for animal studies. An orthotopic human HCC xenograft model was established for analysis of in vivo tumor invasion and metastasis as described in previously. Paraffin-embedded tissue sections (4 μm) were prepared using classical methods and Gal-1, and αv-, and β3-integrin expression levels were classified as either high (≥20% of tumor section) or low (<20% of tumor section) using an immunoperoxidase method. According to the intensity and total area of the staining, Gal-1, and αv- and β3-integrin expression levels were classified as either high (≥20% of tumor section) or low (<20% of tumor section) using an integrated imaging system (Metasphere Imaging System version 3.0; Universal Imaging Corp, Buckinghamshire, UK). Briefly, three representative fields were captured for each case using the Leica Qwin Plus v3 software (Leica Microsystems Inc, Buffalo Grove, IL, USA) under identical settings and magnification (×200). The integrated absorbances and areas of the photographs were measured using Image-Pro Plus v6.0 software (Media Cybernetics, Inc, Bethesda, MD, USA). A uniform setting of color segmentation setting was used for counting the integrated absorbance of each picture.

**Real-time PCR.** Total RNA was extracted using the TRIzol Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions, and real-time PCR was performed using the SYBR Green PCR kit (TaKaRa, Otsu, Japan) according to the manufacturer's instructions. β-actin served as an internal control.

**Statistical analysis.** Statistical analysis was performed using SPSS 16.0 software (Chicago, IL, USA). All tests were two-tailed and P < 0.05 was considered to be statistically significant.

**Conflict of Interest**

The authors declare no conflict of interest.
Acknowledgements. This study was supported by the Open Fund of Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Ministry of Education (KLCC2014-8) and the China Postdoctoral Science Foundation (2014M561410), the National Key Sci-Tech Project (2012ZX10001001-002), the National Natural Science Foundation of China (81472840, 81170233, 81160062, and 81071741) and the Shanghai Municipal Natural Science Foundation (14ZR1405000, 11ZR1428300, 111411a5000). We thank Professor Zonghui Li (State Key Laboratory of Oncogenes & Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine) for providing pwpt-Gal-1, pwpt-Mock, pshRNA-copGFP-Gal-1 shRNA, and pshRNA-copGFP-NC shRNA lentivirus.

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907–1917.
2. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004; 127: S21–S224.
3. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2008; 13: 790–800.
4. Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144: 512–527.
5. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20: 2072–2079.
6. Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB et al. CD151 amplifies signaling by integrin alphaVbeta5 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology 2011; 140: 1623–1641.
7. Ding W, Yau H, Dang H, LeBlanc F, Galicia V, Lu SC et al. Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology 2010; 52: 943–953.
8. Llovet JM, Rocci S, Mazzaferrro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.
9. Copur MS. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 2498.
10. Dufour JF. The evasive promise of antiangiogenic therapy. J Hepatol 2009; 51: 970–972.
11. Ito K, Stannard K, Gabutero E, Clark AM, Neo SY, Onturk S et al. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev 2012; 31: 763–778.
12. Zhang P, Zhang P, Shi B, Zhou M, Jiang H, Zhang H et al. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis 2014; 5: e991.
13. Wei MM, Matsu D, Nestved D, Scrolias A, Romaschin AD, Bjarnason GA et al. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mtTOR signaling axis. Br J Cancer 2014; 110: 1250–1259.
14. Huang XY, Ke AW, Shi GM, Zhang X, Zhang C, Shi YH et al. AlphaB-crystallin complexes with 14-3-3 eta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. Hepatology 2013; 57: 2235–2247.
15. Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013; 5: 345–352.
16. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816–826.
17. Berghoff AS, Kovanda AK, Melchardt T, Barcsh R, Hainfellner JA, Sigos B et al. AlphaVbeta3 and alphaVbeta5 integrins in brain metastases of lung cancer. Clin Exp Metastasis 2013; 31: 841–851.
18. Desgrosellier JS, Lepantre J, Seguin L, Gozo M, Kato S, Franovic A et al. Integrin alphavbeta3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell 2014; 30: 295–308.
19. Kannan N, Nguyen LV, Eawei CJ. Integrin beta3 links therapy resistance and cancer stem cell properties. Nat Cell Biol 2014; 16: 397–399.
20. Seguin L, Kato S, Franovic A, Camargo MF, Lepantre J, Elliott KC et al. An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 2014; 16: 457–468.
21. Martinez-Bosch N, Fernandez-Barrana MG, Moreno M, Ortiz-Zapater E, Munoz-Colado J, Iglesias M et al. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res 2014; 74: 3512–3524.
22. Hsu YL, Wu CY, Hung JY, Lin YS, Huang MS, Kuo PL. Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin alphavbeta4 and Notch1/Jagged2 signaling pathway. Carcinogenesis 2013; 34: 1370–1381.
23. Xia L, Huang W, Tian D, Zhu H, Qi X, Chen Z et al. Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology 2013; 57: 610–624.
24. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 2014; 40: 307–319.
25. Neuzillet C, Tijeras-Raballand A, de Mester L, Clos J, Faivre S, Raymond E. MEK in cancer and cancer therapy. Pharmacol Ther 2014; 141: 160–171.
26. Huang CS, Tang SJ, Chung LY, Yu DP, Ho JY, Cha TL et al. Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer. J Am Soc Nephrol 2014; 25: 1486–1495.
27. Lv B, Yang X, Lv S, Wang L, Fan K, Shi R et al. CXCR4 signaling induced epithelial-mesenchymal transition by PI3K/AKT and EPK pathways in glioblastoma. Mol Neurobiol 2014; 52: 1253–1268.
28. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013; 19: 1438–1449.
29. Yang Y, Cai X, Fan D. Roles of epithelial-mesenchymal transition in cancer drug resistance. Curr Cancer Drug Targets 2013; 13: 915–929.
30. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Baneejee S et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Update 2010; 13: 109–118.
31. van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F et al. Integrin alphaVbeta3 links therapy resistance and cancer stem cell properties. Nat Cell Biol 2013; 15: 1432–1441.
32. Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC, Qin LX et al. miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. J Exp Med 2013; 210: 789–803.
33. Zhang P, Shi B, Gao H, Jiang H, Kong J, Yan J et al. An EpCAM/CD23 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression. Cancer Immunol Immunother 2014; 63: 121–132.

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)